CompletedPhase 2NCT00737516
Centralized Cord Blood Registry to Facilitate Unrelated Cord Blood Transplantation
Studying Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Marrow Donor Program
- Principal Investigator
- John P Miller, M.D., Ph.D.National Marrow Donor Program
- Intervention
- HPC, Cord Blood(biological)
- Enrollment
- 3621 enrolled
- Eligibility
- FEMALE
- Timeline
- 2000 – 2011
Study locations (19)
- StemCyte International Cord Blood Center, Covina, California, United States
- Children's Hospital of Orange County Cord Blood Bank, Orange, California, United States
- Ashley Ross Cord Blood Program, San Diego, California, United States
- University of Colorado Cord Blood Bank, Aurora, Colorado, United States
- Bonfils Cord Blood Service, Denver, Colorado, United States
- Lifeforce Cryobanks, Altamonte Springs, Florida, United States
- Gift of Life Marrow Foundation, Boca Raton, Florida, United States
- LifeCord, Gainesville, Florida, United States
- ITxM Cord Blood Services, Glenview, Illinois, United States
- J.P. McMarthy Cord Stem Cell Bank, Detroit, Michigan, United States
- Michigan Community Blood Centers, Grand Rapids, Michigan, United States
- St. Louis Cord Blood Bank, St Louis, Missouri, United States
- CBS - New Jersey Cord Blood bank, Allendale, New Jersey, United States
- Coriell - New Jersey Cord Blood Bank, Camden, New Jersey, United States
- Carolinas Cord Blood Bank, Durham, North Carolina, United States
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00737516 on ClinicalTrials.govOther trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06303193Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative NeoplasmsNational Cancer Institute (NCI)
- RECRUITINGPHASE3NCT07422480A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood TransfusionsTakeda
- RECRUITINGNANCT07500753A Single-arm, Prospective Study of a Cladribine-Bridged LABU Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory MDS/AML in Elderly PatientsThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE4NCT07486713Olutasidenib DDI Study in Patients With IDH1 Mutation Positive MalignanciesRigel Pharmaceuticals
- RECRUITINGPHASE1NCT07107126Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic SyndromesRemedy Plan, Inc.
- RECRUITINGPHASE1NCT07270978Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDSUniversity of Virginia
- RECRUITINGNANCT06781099Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or MyelofibrosisHospices Civils de Lyon
- RECRUITINGPHASE2NCT07228273Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid LeukemiaOHSU Knight Cancer Institute